|We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.
Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
|Date||Title|| || |
|17-Jul-2018||ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018|
|LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018.At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including:  ... || |
|24-Jun-2018||ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia|
|(GLOBE NEWSWIRE via COMTEX) --- Focuses development efforts on solid tumor indications
- Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic cancer, in addition to ongoing launch of Phase 3 trial in second-line pancreatic cancer.
- Expands eryaspase production capacity in the United States and France
- Plans to cease development in acute lymphoblastic leukemia (ALL), including withdrawal of European Marketing Authorization Application (MAA)
... || |
|20-Jun-2018||ERYTECH to Present at JMP Securities Life Science Conference|
|(GLOBE NEWSWIRE via COMTEX) --LYON, France, June 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the JMP Securities Life Science Conference, June 20, 2018 at The St. Regis, New York, in New York City. Conference Details: - Conference:&nbs... || |
|15-Jun-2018||ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018|
|LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment ... || |
|09/11/18 2:30 p.m. CET|
|Erytech Pharma Second Quarter 2018 Conference Call and Webcast|
|11/13/18 2:30 p.m. CET|
|Erytech Pharma Third Quarter 2018 Conference Call and Webcast|
| Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.|
ERYTECH Pharma complies with GDPR regulations. For more information about your data, please click here.